Home | Community | Get Involved | Donate | | Site Index | Search Go Button
The mark, American Cancer Society, is a registered trademark of the American Cancer Society, Inc., and may not be copied, reproduced, transmitted, displayed, performed, distributed, sublicensed, altered, stored for subsequent use or otherwise used in whole or in part in any manner without ACS's prior written consent.
 
My Planner Register | Sign In Sign In


Cancer Reference Information
 
    All About This Topic
Other Information Sources
Glossary
Cancer Drug Guide
Treatment Options
Treatment Decision Tools
   
Detailed Guide: Nasal Cavity and Paranasal Cancer
How Are Nasal Cavity and Paranasal Sinus Cancers Staged?

The prognosis (outlook) for people with cancers of the nasal cavity and paranasal sinuses depends on many factors. These include the type of cancer, the size and location of the cancer, whether the cancer has spread to other areas of the body, and the general health of the patient. Cancers of the nasal cavity and paranasal sinuses first grow or spread locally (to nearby areas) and then spread to the lymph nodes. Lymph nodes are bean-sized glands scattered throughout the head and neck (and the rest of the body) which fight infection and remove cell waste.

Staging is a process that tells the doctor how widespread a cancer may be. It will show whether the cancer has spread and how far. The treatment and outlook for nasal cavity or paranasal sinus cancers depend, to a large extent, on their stage. For early cancer, surgery may be all that is needed. For more advanced cancer, other treatments such as chemotherapy or radiation therapy may be required. Be sure to ask your doctor to explain the stage of your cancer so that you can make the best choice for yourself about your treatment.

Nasal cavity and paranasal sinus cancers are staged using a system that is agreed upon by the American Joint Committee on Cancer (AJCC).The AJCC/TNM System describes the extent of the primary tumor (T), the absence or presence of metastasis to nearby lymph nodes (N), and the absence or presence of distant metastasis (M). Information about the T, N, and M categories is then combined by a process called stage grouping to determine the patient’s stage. This stage is described in Roman numerals from 0 to IV.

T categories for maxillary sinus cancer

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

Tis: Cancer cells are limited to the innermost layer of the mucosa (epithelium). These cancers are known as carcinoma in situ.

T1: Tumor is only in the tissue lining the sinus (the mucosa) and does not invade bone

T2: Tumor begins to grow into some of the bones of the sinus. (Note: If the cancer grows into the bone of the back part of the sinus, it is classified as T3).

T3: Tumor begins to grow into the bone at the back of the sinus (called the posterior wall) or the tumor has grown into the ethmoid sinus, the tissues under the skin, or the eye socket.

T4a: Tumor grows into other structures such as the skin of the cheek, the eye, the bone at the top of the nose (cribiform plate), the sphenoid sinus, the frontal sinus, or certain parts of the face (the pterygoid plates and the infratemporal fossa).

T4b: Tumor has grown into the area between the nasal cavity and the throat (called the nasopharynx), the brain, the tissue covering the brain (the dura), some parts of the skull (middle cranial fossa, the clivus), or certain nerves.

T categories for nasal cavity and ethmoid sinus cancer

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

Tis: Cancer cells are only in the innermost layer of the mucosa (epithelium). These cancers are known as carcinoma in situ.

T1: Tumor is only in the nasal cavity or one of the ethmoid sinuses, although it may have grown into the bones of the sinus.

T2: Tumor has grown into other nasal or paranasal cavities

T3: Tumor has grown into bone of the eye socket, the roof of the mouth (palate), the cribiform plate (the bone that separates the nose from the brain), and/or the maxillary sinus

T4a: Tumor has grown into other structures such as the eye, the skin of the nose, the skin of the cheek, the sphenoid sinus, the frontal sinus, or certain bones in the face (pterygoid plates). Cancers that areT4a are resectable (meaning they can be removed with surgery)

T4b: Tumor is growing into the back of the eye socket, the brain, the dura (the tissue covering the brain), some parts of the skull (the clivus, the middle cranial fossa), certain nerves, or the nasopharynx (the area between the nasal cavity and the throat). Tumors are called T4b when they are not resectable (they cannot be removed with surgery)

N categories

NX: Nearby (regional) lymph nodes cannot be assessed

N0: Cancer has not spread into the lymph nodes

N1: Cancer has spread to a single lymph node that is on the same side as the tumor and is no larger than 3 cm (slightly larger than 1 inch)

N2: Cancer has spread to a lymph node that is larger than 3 cm (slightly larger than one inch) but smaller than 6 centimeters (slightly larger than 2 inches); or cancer has spread to more than one lymph node which are smaller than 6 cm; or cancer is in a lymph node that is not on the same side as the tumor (and the lymph node is smaller than 6 cm).

N3: Cancer has spread to at least one nearby lymph node that is larger than 6 cm (slightly larger than 2 inches)

M categories

MX: Metastasis cannot be assessed

M0: No distant metastasis

M1: Metastasis present to distant organs such as the lung, brain, or liver.

Stage groupings


Stage T N M
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1 or T2 N1 M0
  T3 N0 or N1 M0
Stage IVA T1, T2, or T3 N2 M0
  T4a N0, N1, or N2 M0
Stage IVB Any T N3 M0
  T4b Any N M0
Stage IVC Any T Any N M1

Survival by stage

The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed. Many of these patients live much longer than 5 years after diagnosis, and 5-year rates are used to produce a standard way of discussing prognosis. Five-year relative survival rates assume that some people will die of other causes and compare the observed survival with that expected for people without the cancer. These are considered to be a more accurate way to describe the outlook for patients with a particular type and stage of cancer. Of course, 5-year survival rates are based on patients diagnosed and initially treated more than 5 years ago. Improvements in treatment since then may result in a more favorable outlook for recently diagnosed patients.

The following statistics come from the National Cancer Institute's SEER database and are based on cancers diagnosed between 1988 and 2001. This database does not list these cancers by AJCC stage, but instead groups them into local, regional and distant stages. Local stage means that there is no sign that the cancer has spread outside of the nose or sinus (where it started). This corresponds to AJCC stages I and II. Regional means that the cancer has started growing into nearby structure or lymph nodes. This corresponds to stages III, IVA, and IVB. Distant means that the cancer has spread to distant sites, such as the lung or liver. This corresponds to stage IVC.

For all nasal cavity and paranasal sinus cancers combined, the relative 5-year survival is 54%. Survival tends to worsen as the stage increases:


Stage 5-year relative survival
Localized 83%
Regional 47%
Distant 25%

For nasal cavity cancers, survival is slightly better:


Stage 5-year relative survival
Localized 86%
Regional 57%
Distant 38%

Last Medical Review: 08/13/2009
Last Revised: 08/13/2009

Printer-Friendly Page
Email this Page
Detailed Guide
What Is It?
Causes, Risk Factors and Prevention
Early Detection, Diagnosis, Staging
Treating Nasal Cavity and Paranasal Cancer
Talking With Your Doctor
More Information
Related Tools & Topics
Prevention & Early Detection  
Bookstore  
Circle Of Sharing: Personalize Your Cancer Information  
Not registered yet?
  Register now or see reasons to register.  
Help |  About ACS |  Employment & Volunteer Opportunities |  Legal & Privacy Information |  Press Room
Copyright 2009 © American Cancer Society, Inc.
All content and works posted on this website are owned and
copyrighted by the American Cancer Society, Inc. All rights reserved.